EGFR and non-small cell lung carcinoma: In the multicenter, open-label, randomized phase II OptiTROP-Lung03 trial (NCT05631262), the TROP2-directed ADC sacituzumab tirumotecan was evaluated in patients with advanced EGFR-mutant NSCLC who had progressed on osimertinib and platinum-based chemotherapy but had no identifiable resistance mechanism.